Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance

被引:35
作者
Geitmann, M
Unge, T
Danielson, UH
机构
[1] Uppsala Univ, Dept Biochem & Organ Chem, SE-75123 Uppsala, Sweden
[2] Uppsala Univ, Dept Cell & Mol Biol, SE-75123 Uppsala, Sweden
关键词
D O I
10.1021/jm0504050
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To decipher the mechanism for non-nucleoside inhibitor resistance of HIV-1 reverse transcriptase, the kinetics of the interaction between wild type and drug-resistant variants of the enzyme and structurally diverse inhibitors were determined. Substitution of amino acid residues in the inhibitor binding site resulted in altered rate constants for the pre-equilibrium between two unliganded forms of the enzyme, and for the association and dissociation of the inhibitor-enzyme interaction. The Y181C, V1081, and P225H substitutions affected primarily the association and dissociation rate constants, while the K103N and the L100I substitutions also influenced the equilibrium between the two forms of the free enzyme. The K103N and the L100I substitutions were found to facilitate both the entry of the inhibitor into the binding pocket as well as its exit, in contrast to what has been reported elsewhere. Interaction kinetic-based resistance profiles showed that phenethylthiazolylthiourea compounds were relatively insensitive to the studied substitutions.
引用
收藏
页码:2375 / 2387
页数:13
相关论文
共 41 条
[1]   TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].
Andries, K ;
Azijn, H ;
Thielemans, T ;
Ludovici, D ;
Kukla, M ;
Heeres, J ;
Janssen, P ;
De Corte, B ;
Vingerhoets, J ;
Pauwels, R ;
de Béthune, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686
[2]   HIGHLY SPECIFIC-INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BY A NOVEL 6-SUBSTITUTED ACYCLOURIDINE DERIVATIVE [J].
BABA, M ;
TANAKA, H ;
DECLERCQ, E ;
PAUWELS, R ;
BALZARINI, J ;
SCHOLS, D ;
NAKASHIMA, H ;
PERNO, CF ;
WALKER, RT ;
MIYASAKA, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (03) :1375-1381
[3]   Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy [J].
Bacheler, LT ;
Anton, ED ;
Kudish, P ;
Baker, D ;
Bunville, J ;
Krakowski, K ;
Bolling, L ;
Aujay, M ;
Wang, XV ;
Ellis, D ;
Becker, MF ;
Lasut, AL ;
George, HJ ;
Spalding, DR ;
Hollis, G ;
Abremski, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2475-2484
[4]  
Balzarini J, 1996, MOL PHARMACOL, V49, P882
[5]   Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine) [J].
Balzarini, J ;
Pelemans, H ;
Riess, G ;
Roesner, M ;
Winkler, I ;
De Clercq, E ;
Kleim, JP .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (05) :617-625
[6]   Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 [J].
Balzarini, J .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) :921-944
[7]   Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection [J].
Buckheit, RW .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (08) :1423-1442
[8]   2-amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1 [J].
Chan, JH ;
Hong, JS ;
Hunter, RN ;
Orr, GF ;
Cowan, JR ;
Sherman, DB ;
Sparks, SM ;
Reitter, BE ;
Andrews, CW ;
Hazen, RJ ;
St Clair, M ;
Boone, LR ;
Ferris, RG ;
Creech, KL ;
Roberts, GB ;
Short, SA ;
Weaver, K ;
Ott, RJ ;
Ren, JS ;
Hopkins, A ;
Stuart, DI ;
Stammers, DK .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (12) :1866-1882
[9]   Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1 [J].
Corbett, JW ;
Ko, SS ;
Rodgers, JD ;
Jeffrey, S ;
Bacheler, LT ;
Klabe, RM ;
Diamond, S ;
Lai, CM ;
Rabel, SR ;
Saye, JA ;
Adams, SP ;
Trainor, GL ;
Anderson, PS ;
Erickson-Viitanen, SK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) :2893-2897
[10]   Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors [J].
Das, K ;
Lewi, PJ ;
Hughes, SH ;
Arnold, E .
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2005, 88 (02) :209-231